Análisis Argos
CRSP
CRSPSin veredicto2 señales de riesgo
CRISPR Therapeutics AG · Healthcare
US$ 47.55
precio al 2026-07-28
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
21/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Sin recompensas destacadas.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
!Piotroski F-Score débil (1/9)
!FCF negativo con deuda creciente
VALOR0/6FUTURO6/6PASADO0/6SALUD2/6DIVIDENDO1/6
El Iris de calidad
VALOR0/6FUTURO6/6PASADO0/6SALUD2/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial débil
SaludBalance razonable
DividendoEl dividendo aún duerme
Score Argos21de 100Sin veredicto
Ingresos▼100%
US$ 0 B
Margen operativo▲1115%
-16191.4%
Flujo de caja libre▲150%
US$ -0.4 B
Deuda neta
US$ 0 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 4.6B
P/E—
EV/EBITDA—
FCF yield-7.5%
ROIC-29%
Margen operativo-16191.4%
Crecim. ingresos-90.0%/año
Piotroski F1/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 10 jul
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
fool.com · 10 jul
3 Reasons to Buy CRISPR Therapeutics Stock
CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.
fool.com · 8 jul
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
zacks.com · 7 jul
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
fool.com · 7 jul
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.
schaeffersresearch.com · 7 jul
Progress Report: How Our Top Stock Picks of 2026 Are Faring
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
fool.com · 7 jul
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.
fool.com · 6 jul
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.